The ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast track clinical trials of an indigenous COVID-19 vaccine.
The ICMR has partnered with Bharat Biotech International Limited(BBIL) to fast track clinical trials of the indigenous COVID-19 vaccine, BBV152.
This is the first indigenous vaccine to be developed in India and is one of the top priority projects which is being monitored at the topmost level of the Government. The vaccine is derived from a strain of SARS- Cov-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical and development of this vaccine.
It is believed the vaccine can be launched for public use by August 15 after completion of all clinical trials. BBIL is working expeditiously to meet the target; however final outcome will depend on the cooperation of all clinical trial sites involved in this project.
BBIL has advised to speedily process all approvals related to initiation of the clinical trial and ensure that the subject enrollment is initiated no later than 7th of July .